Zomelis 50mg Tablet contains Vildagliptin, a potent dipeptidyl peptidase-4 (DPP-4) inhibitor indicated for the management of type 2 diabetes mellitus. By selectively inhibiting the DPP-4 enzyme, Vildagliptin enhances the levels of incretin hormones, which increase insulin secretion and decrease glucagon release in a glucose-dependent manner, thereby improving glycemic control. Zomelis is prescribed as monotherapy or in combination with other antidiabetic agents such as metformin or insulin when diet and exercise alone do not achieve adequate glycemic control. The recommended dosage is 50mg once or twice daily, depending on the patient’s glycemic status and concomitant therapies. Clinical studies have demonstrated that Vildagliptin effectively lowers HbA1c levels with a low risk of hypoglycemia and neutral effects on body weight. It is generally well tolerated, with the most common adverse effects including mild gastrointestinal disturbances and headache. Caution is advised in patients with hepatic or renal impairment, and regular monitoring of liver function tests is recommended. Zomelis should be used as part of a comprehensive diabetes management plan involving lifestyle modifications, and patients should be educated on recognizing symptoms of hypoglycemia and the importance of adherence to therapy.